Abstract:BACKGROUND:Lung adenocarcinoma (LUAD) is the most common histologic subtype of lung cancer and has a high risk of distant metastasis at every disease stage. We aimed to characterize the genomic landscape of LUAD and identify mutation signatures associated with tumor progression.METHODS AND FINDINGS:We performed an integrative genomic analysis, incorporating whole exome sequencing (WES), determination of DNA copy number and DNA methylation, and transcriptome sequencing for 101 LUAD samples from the Environment And Genetics in Lung cancer Etiology (EAGLE) study. We detected driver genes by testing whether the nonsynonymous mutation rate was significantly higher than the background mutation rate and replicated our findings in public datasets with 724 samples. We performed subclonality analysis for mutations based on mutant allele data and copy number alteration data. We also tested the association between mutation signatures and clinical outcomes, including distant metastasis, survival, and tumor grade. We identified and replicated two novel candidate driver genes, POU class 4 homeobox 2 (POU4F2) (mutated in 9 [8.9%] samples) and ZKSCAN1 (mutated in 6 [5.9%] samples), and characterized their major deleterious mutations. ZKSCAN1 was part of a mutually exclusive gene set that included the RTK/RAS/RAF pathway genes BRAF, EGFR, KRAS, MET, and NF1, indicating an important driver role for this gene. Moreover, we observed strong associations between methylation in specific genomic regions and somatic mutation patterns. In the tumor evolution analysis, four driver genes had a significantly lower fraction of subclonal mutations (FSM), including TP53 (p = 0.007), KEAP1 (p = 0.012), STK11 (p = 0.0076), and EGFR (p = 0.0078), suggesting a tumor initiation role for these genes. Subclonal mutations were significantly enriched in APOBEC-related signatures (p < 2.5×10-50). The total number of somatic mutations (p = 0.0039) and the fraction of transitions (p = 5.5×10-4) were associated with increased risk of distant metastasis. Our study's limitations include a small number of LUAD patients for subgroup analyses and a single-sample design for investigation of subclonality.CONCLUSIONS:These data provide a genomic characterization of LUAD pathogenesis and progression. The distinct clonal and subclonal mutation signatures suggest possible diverse carcinogenesis pathways for endogenous and exogenous exposures, and may serve as a foundation for more effective treatments for this lethal disease. LUAD's high heterogeneity emphasizes the need to further study this tumor type and to associate genomic findings with clinical outcomes.

Molecular fingerprints of nuclear genome and mitochondrial genome for early diagnosis of lung adenocarcinoma

Comprehensive Investigation of Mutational Features of Various Lung Adenocarcinoma Histological Subtypes among Chinese Patients.

Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study

Novel genome-wide DNA methylation profiling reveals distinct epigenetic landscape, prognostic model and cellular composition of early-stage lung adenocarcinoma

Identification of Genes Associated with Lung Adenocarcinoma Prognosis

[Progress in Single-cell RNA Sequencing of Lung Adenocarcinoma]

Deciphering Cell Lineage Specification of Human Lung Adenocarcinoma with Single-Cell RNA Sequencing

Integrative Proteomic Characterization of Human Lung Adenocarcinoma

Integrative Analysis of DNA Methylomes Reveals Novel Cell-Free Biomarkers in Lung Adenocarcinoma.

Comprehensive analysis of lung adenocarcinoma: Unveiling differential gene expression, survival‐linked genes, subtype stratification, and immune landscape implications

Identification of lung adenocarcinoma subtypes based on mitochondrial energy metabolism-related genes

Genomic landscape and tumor mutational features of resected preinvasive to invasive lung adenocarcinoma

Genomic and Immune Profiling of Pre-Invasive Lung Adenocarcinoma.

Differentially Expressed Mutant Genes Reveal Potential Prognostic Markers For Lung Adenocarcinoma.

Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma

Radiomics-based Support Vector Machine Distinguishes Molecular Events Driving Progression of Lung Adenocarcinoma

Integrated 5-hydroxymethylcytosine and fragmentation signatures as enhanced biomarkers in lung cancer

Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution

Identification of Biomarkers for the Detection of Early Stage Lung Adenocarcinoma by Microarray Profiling of Long Noncoding RNAs.

Genomic and Transcriptomic Dynamics in the Stepwise Progression of Lung Adenocarcinoma

Integrated Analysis of Single-Cell and Bulk RNA Sequencing Reveals a Malignancy-Related Signature in Lung Adenocarcinoma.